TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34543432

Group type: EXPERIMENTAL
Intervention: SQ-LNS (small-quantity lipid-based nutrient supplements)
Number of subjects: 2711
Study: 32854664

Group type: EXPERIMENTAL
Intervention: PRISMS application
Number of subjects: 12
Study: 35678594

Group type: EXPERIMENTAL
Intervention: S1 maintenance therapy (S1-MT)
Number of subjects: 183
Study: 36734446

Group type: EXPERIMENTAL
Intervention: Standard sedation supplemented by magnesium sulfate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented by correction of hypomagnesemia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard sedation therapy with benzodiazepines)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3 (Dexmedetomidine + magnesium)
Number of subjects: 80
Study: 32122618

Group type: EXPERIMENTAL
Intervention: E‐cigarette vapor with nicotine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: E‐cigarette vapor without nicotine
Number of subjects: 17
Study: 34028656

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy plus Amitriptyline
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 135
Study: 34666255

Group type: EXPERIMENTAL
Intervention: Short-term lifestyle intervention (4 weeks)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year
Number of subjects: 156
Study: 35074280

Group type: EXPERIMENTAL
Intervention: Psychosocial factors including coping and self-efficacy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Coping catastrophizing and self-efficacy
Number of subjects: 80
Study: 34303343

Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cRM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANCOVAI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANCOVAII
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANOVA-Change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34774725

Group type: EXPERIMENTAL
Intervention: Vitamin D metabolites (25(OH)D, 25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3‐Epi‐D3)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 277

Group type: COMPARATOR
Intervention: Overweight and obese subjects
Number of subjects: 277
Study: 33429812

Group type: EXPERIMENTAL
Intervention: Lifestyle education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32453393

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU daily for 6 months)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Fish oil (1000 mg daily for 6 months)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 35241076

Group type: EXPERIMENTAL
Intervention: Modified Safe Childbirth Checklist (mSCC) with PRONTO® simulation training and quality improvement (QI) activities
Number of subjects: 21472

Group type: COMPARATOR
Intervention: Control sites without the modified SCC and PRONTO/QI support
Number of subjects: 21472
Study: 33484479

Group type: EXPERIMENTAL
Intervention: Oral probiotic therapy (Lactobacillus fermentum CECT5716)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 35151143

Group type: COMPARATOR
Intervention: LMA Fastrach™
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: iLTS-D™
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 99
Study: 34472881

Group type: EXPERIMENTAL
Intervention: Rumination about obsessive-compulsive symptoms
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Rumination about mood
Number of subjects: 145

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 145
Study: 32769027

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (n = 65)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham CPAP (n = 61)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Adherent therapeutic CPAP use in patients with baseline depression
Number of subjects: 126
Study: 34602460

Group type: EXPERIMENTAL
Intervention: sl‐wIRAR treatment (2 treatments/day for 30 min each for 6 days)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: sl‐wIRAR treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 71
Study: 32701652

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Calcitonin gene‐related peptide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Middle cerebral artery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Superficial temporal artery
Number of subjects: 34
Study: 32224045

Group type: EXPERIMENTAL
Intervention: Disease flare during tapering of DMARDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (well-controlled RA without flare)
Number of subjects: 0
Study: 34091567

Group type: EXPERIMENTAL
Intervention: Simulation-Based Mastery Learning (SBML)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 0
Study: 33150703

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cell (BMMSC) therapy plus rehabilitation therapy and risperidone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rehabilitation therapy and risperidone
Number of subjects: 32
Study: 34139763

Group type: EXPERIMENTAL
Intervention: Community-based physical rehabilitation program (3 months of supervised exercise training followed by 9 months of self-managed exercise)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Community-based physical rehabilitation program
Number of subjects: 164

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 164
Study: 36501070

Group type: EXPERIMENTAL
Intervention: Betaine anhydrous (BET) 6 g/day for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cellulose placebo (PLA) 6 g/day for 14 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-load (HL; 70% 1RM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-load Blood Flow Restriction (LL-BFR; 20% 1RM at 80% arterial occlusion pressure)
Number of subjects: 18
Study: 33745627

Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (300 mg, 1.2%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo mouth rinse (microcrystalline cellulose)
Number of subjects: 10
Study: 32233107

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. every 3 weeks
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg i.v. every 3 weeks plus Bevacizumab 15 mg/kg i.v. every 3 weeks
Number of subjects: 305

Group type: COMPARATOR
Intervention: Sunitinib 50 mg orally daily (4 weeks on, 2 weeks off)
Number of subjects: 305
Study: 36031721

Group type: EXPERIMENTAL
Intervention: Pathologic microvascular invasion group, n = 146
Number of subjects: 311

Group type: COMPARATOR
Intervention: No pathologic microvascular invasion group, n = 165
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Nomogram model created in the training cohort
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Nomogram model validated in the validation cohort
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Calibration curve analysis
Number of subjects: 311
Study: 33091149

Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Periodontitis + CHD
Number of subjects: 122

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 122

Group type: COMPARATOR
Intervention: CHD
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 122
Study: 34780207

Group type: EXPERIMENTAL
Intervention: Weekly session frequency
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) group (attenuated session frequency)
Number of subjects: 1322
Study: 33296526

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Variceal Band Ligation (VBL)
Number of subjects: 152
Study: 36283827

Group type: EXPERIMENTAL
Intervention: GSK2881078 (females: 1.0 mg; males: 2.0 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 33221392

Group type: EXPERIMENTAL
Intervention: Exercise prior to stress
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 32271053

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 108
Study: 36477032

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy only (experimental group)
Number of subjects: 17980

Group type: COMPARATOR
Intervention: Systematic biopsy and MRI-targeted biopsy (reference group)
Number of subjects: 17980

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17980
Study: 34319986

Group type: EXPERIMENTAL
Intervention: Sanitation intervention (improved dual-pit latrine, tools for child/animal feces management, behavioral messaging)
Number of subjects: 1405

Group type: COMPARATOR
Intervention: Control group (no sanitation intervention)
Number of subjects: 1405
Study: 32749941

Group type: EXPERIMENTAL
Intervention: Combined adjuvant chemotherapy and radiotherapy (CTRT)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 423
Study: 35545644

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal cord stimulation (tSCS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buspirone (busp)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buspirone plus tSCS
Number of subjects: 10
Study: 32247072

Group type: EXPERIMENTAL
Intervention: Primary percutaneous intervention (PPCI) in patients with reciprocal ST-segment depression (Group A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Primary percutaneous intervention (PPCI) in patients without reciprocal ST-segment depression (Group B)
Number of subjects: 112
Study: 36048026

Group type: EXPERIMENTAL
Intervention: axi-cel
Number of subjects: 0

Group type: COMPARATOR
Intervention: liso-cel
Number of subjects: 0
Study: 33600899

Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes measures (PROMs)
Number of subjects: 215
Study: 32985001

Group type: EXPERIMENTAL
Intervention: Fermented barley - wheat flour compound noodle (FBWN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole wheat noodles (WWN)
Number of subjects: 0
Study: 35905985

Group type: EXPERIMENTAL
Intervention: Progressive exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-home exercise
Number of subjects: 0
Study: 33463899

Group type: EXPERIMENTAL
Intervention: High-intensity intervals (30 minutes, 10, 1-minute intervals at 85% heart-rate reserve)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (45 minutes at 50% heart-rate reserve)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (30 minutes quiet rest)
Number of subjects: 9
Study: 32869580

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Hydroprednisone (2 mg•kg‐1•d‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydroprednisone (2 mg•kg‐1•d‐1)
Number of subjects: 60
Study: 35441396

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Clodronate with NSAIDs
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Clodronate without NSAIDs
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1082
Study: 33930795

Group type: EXPERIMENTAL
Intervention: Nomogram based on easily obtainable parameters
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 1620
Study: 32035708

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetravalent Inactivated Influenza Vaccine (TIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza vaccination followed bacterial inoculation
Number of subjects: 0
Study: 35357766

Group type: EXPERIMENTAL
Intervention: Baseline MMP9 levels in quintile Q5 (highest quintile)
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Baseline MMP9 levels in quintile Q3 (reference group)
Number of subjects: 3014

Group type: EXPERIMENTAL
Intervention: Higher MMP9 ratios
Number of subjects: 3014
Study: 36208364

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg once daily
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1776
Study: 34704974

Group type: EXPERIMENTAL
Intervention: Compressive palatal stents (CPSGs)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 144
Study: 32343000

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Autologous placebo
Number of subjects: 49
Study: 35786390

Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion (EASI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravaginal isoniazid (INH)
Number of subjects: 150
Study: 32701172

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 22
Study: 32653075

Group type: EXPERIMENTAL
Intervention: High-dose MF–IND (320 μg, 150 μg) once daily
Number of subjects: 2216

Group type: EXPERIMENTAL
Intervention: Medium-dose MF–IND (160 μg, 150 μg) once daily
Number of subjects: 2216

Group type: COMPARATOR
Intervention: High-dose MF (800 μg [400 μg twice daily])
Number of subjects: 2216

Group type: COMPARATOR
Intervention: Medium-dose MF (400 μg once daily)
Number of subjects: 2216

Group type: COMPARATOR
Intervention: High-dose FLU–SAL (500 μg, 50 μg) twice daily
Number of subjects: 2216
Study: 35022769

Group type: EXPERIMENTAL
Intervention: Hookah lounges
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Vape shops
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: All tobacco retailers
Number of subjects: 479
Study: 34858404

Group type: EXPERIMENTAL
Intervention: CoronaVac
Number of subjects: 0
Study: 35379298

Group type: EXPERIMENTAL
Intervention: Diabetes management strategy using an information board and a mobile application
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1440
Study: 34650220

Group type: EXPERIMENTAL
Intervention: AI-based inference of retinal function using deep-learning software
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: AI-based inference of retinal function with patient-specific baseline data
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Prediction of month 7-8 post-treatment retinal sensitivity from baseline SD-OCT data
Number of subjects: 57
Study: 32650533

Group type: EXPERIMENTAL
Intervention: Acemannan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 50
Study: 36053133

Group type: EXPERIMENTAL
Intervention: Structured scenes with four pairs of co-occurring distractor shapes
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Unstructured scenes with eight distractor shapes randomly partitioned into four pairs
Number of subjects: 1140
Study: 33712062

Group type: EXPERIMENTAL
Intervention: Preference-informed complementary trial (PICT) design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional randomized controlled trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preference-informed designs
Number of subjects: 0
Study: 32779505

Group type: EXPERIMENTAL
Intervention: Epeleuton 2 g/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 615730633

Group type: EXPERIMENTAL
Intervention: Parenteral diazepam bolus
Number of subjects: 96

Group type: COMPARATOR
Intervention: Parenteral diazepam continuous infusion
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined treatment (bolus and infusion)
Number of subjects: 96
Study: 36098361

Group type: EXPERIMENTAL
Intervention: Endothelium corneum gigeriae galli
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 34377934

Group type: EXPERIMENTAL
Intervention: Adjuvant clodronate (1600 mg daily for 3 years)
Number of subjects: 1883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1883
Study: 32286643

Group type: EXPERIMENTAL
Intervention: Vaccine (20 µg, n = 201)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (n = 199)
Number of subjects: 400
Study: 35033949

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 140
Study: 33045330

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) 133 mg with 7.5 mL of 0.5% and 7.5 mL of 0.25% plain bupivacaine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Plain bupivacaine 25 mL of 0.5%
Number of subjects: 104
Study: 35616780

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Video exercise
Number of subjects: 19
Study: 34334695

Group type: EXPERIMENTAL
Intervention: Upper limb injuries
Number of subjects: 6662

Group type: COMPARATOR
Intervention: Lower limb injuries
Number of subjects: 6662

Group type: COMPARATOR
Intervention: Spica casts (single leg)
Number of subjects: 6662

Group type: COMPARATOR
Intervention: Spica casts (one and a half leg)
Number of subjects: 6662

Group type: COMPARATOR
Intervention: Spica casts (two leg)
Number of subjects: 6662

Group type: EXPERIMENTAL
Intervention: Experienced daycare facilities (>5 years)
Number of subjects: 6662
Study: 33254286

Group type: EXPERIMENTAL
Intervention: Subgroup analyses reported in HF RCTs
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Subgroup effect claims for primary outcome
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Interaction testing for subgroup claims
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Credibility criteria satisfaction
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Justification of subgroup choice
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Power to detect differences within subgroups
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Influence of funding source on reporting
Number of subjects: 261
Study: 36116033

Group type: EXPERIMENTAL
Intervention: Expedited TAVR
Number of subjects: 142
Study: 33229024

Group type: EXPERIMENTAL
Intervention: Chinese version of the Snaith-Hamilton Pleasure Scale (SHAPS)
Number of subjects: 5054
Study: 33270911

Group type: EXPERIMENTAL
Intervention: chronoIFLO5 (irinotecan 180 mg/sqm, oxaliplatin 80 mg/sqm, fluorouracil 2800 mg/sqm, leucovorin 1200 mg/sqm) administered every 3 weeks for 5 days
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: chronoIFLO5
Number of subjects: 193
Study: 35416742

Group type: EXPERIMENTAL
Intervention: face-to-face plus monitored home exercise
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: only monitored home-based exercise
Number of subjects: 150

Group type: COMPARATOR
Intervention: control
Number of subjects: 150
Study: 32205276

Group type: EXPERIMENTAL
Intervention: 3-D printed porous titanium implants
Number of subjects: 49

Group type: COMPARATOR
Intervention: PEEK with autograft (control)
Number of subjects: 49
Study: 616854365

Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension (KT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Kinesio Taping without tension (placebo)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (ten minutes of rest)
Number of subjects: 36
Study: 33517368

Group type: EXPERIMENTAL
Intervention: Spaced retrieval practice (SRP) with self-generation booster
Number of subjects: 41

Group type: COMPARATOR
Intervention: Massed study control condition
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Spaced retrieval practice (SRP)
Number of subjects: 41
Study: 32917189

Group type: EXPERIMENTAL
Intervention: Step-by-step teaching method
Number of subjects: 68

Group type: COMPARATOR
Intervention: All-in-one teaching method
Number of subjects: 68
Study: 35105638

Group type: EXPERIMENTAL
Intervention: Delphi survey
Number of subjects: 53
Study: 34388297

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg/d
Number of subjects: 17
Study: 35100917

Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin (60 mg/m2 administered on days 1 and 3, 30 mg/m2 each time) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group treated with cisplatin (60 mg/m2 intravenously) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HIPEC group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 33836364

Group type: EXPERIMENTAL
Intervention: 7-week psychoeducation intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 12
Study: 35346549

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 14 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 32796950

Group type: EXPERIMENTAL
Intervention: NRM-J index applied to patients in the validation set
Number of subjects: 2344

Group type: EXPERIMENTAL
Intervention: NRM-J index
Number of subjects: 2344
Study: 33345865

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study: 33428860

Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Number of previous corticosteroid infiltrations
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Longer time from symptom onset to surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smoker status
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presence of prior lumbosacral fusion (LSF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fibromyalgia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 60